The Experts below are selected from a list of 6012 Experts worldwide ranked by ideXlab platform
Muin J. Khoury - One of the best experts on this subject based on the ideXlab platform.
-
Genetics and Genomics in Public Health
Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics, 2019Co-Authors: Debra Lochner Doyle, Muin J. KhouryAbstract:Abstract This chapter reviews the emergence and progress in the field of Public Health genetics/Genomics. Firmly rooted in two fields with a rich and disparate history (medical genetics and Public Health), Public Health Genomics has taken shape only in the past 20 years. Broadly defined, Public Health Genomics is a multidisciplinary field concerned with the responsible and effective translation of genomic science and technologies to improve population Health. In contrast to medical genetics, where the unit of intervention is the individual and other family members, Public Health Genomics is concerned with the Health and well-being of a whole population or community, no matter how it is defined. We review the goals and activities of Public Health, discuss Public Health essential services in the context of genetics/Genomics, and give examples of ongoing priorities and activities in the field, such as hereditary cancers, pathogen Genomics, precision medicine, and integrating evidence-based Genomics applications into the changing landscape of community-based Healthcare. Moving forward, the role of Public Health Genomics is expected to expand due to rapid developments and applications of Genomics in Healthcare and disease prevention, requiring further assessment, policy development, and assurance efforts.
-
Beyond Public Health Genomics: Can Big Data and Predictive Analytics Deliver Precision Public Health?
Public health genomics, 2018Co-Authors: Muin J. Khoury, Michael M. Engelgau, David A. Chambers, George A. MensahAbstract:The field of Public Health Genomics has matured in the past two decades and is beginning to deliver genomic-based interventions for Health and Health care. In the past few years, the terms precision medicine and precision Public Health have been used to include information from multiple fields measuring biomarkers as well as environmental and other variables to provide tailored interventions. In the context of Public Health, "precision" implies delivering the right intervention to the right population at the right time, with the goal of improving Health for all. In addition to Genomics, precision Public Health can be driven by "big data" as identified by volume, variety, and variability in biomedical, sociodemographic, environmental, geographic, and other information. Most current big data applications in Health are in elucidating pathobiology and tailored drug discovery. We explore how big data and predictive analytics can contribute to precision Public Health by improving Public Health surveillance and assessment, and efforts to promote uptake of evidence-based interventions, by including more extensive information related to place, person, and time. We use selected examples drawn from child Health, cardiovascular disease, and cancer to illustrate the promises of precision Public Health, as well as current methodologic and analytic challenges to big data to fulfill these promises.
-
From Public Health Genomics to precision Public Health: a 20-year journey.
Genetics in medicine : official journal of the American College of Medical Genetics, 2017Co-Authors: Muin J. Khoury, M. Scott Bowen, Mindy Clyne, W. David Dotson, Marta Gwinn, Ridgely Fisk Green, Katherine Kolor, Juan L. Rodriguez, Anja WulfAbstract:In this paper, we review the evolution of the field of Public Health Genomics in the United States in the past two decades. Public Health Genomics focuses on effective and responsible translation of genomic science into population Health benefits. We discuss the relationship of the field to the core Public Health functions and essential services, review its evidentiary foundation, and provide examples of current US Public Health priorities and applications. We cite examples of Publications to illustrate how Genetics in Medicine reflected the evolution of the field. We also reflect on how Public-Health Genomics is contributing to the emergence of “precision Public Health” with near-term opportunities offered by the US Precision Medicine (AllofUs) Initiative.
-
Public Health Genomics: Using Genetic Information to Improve Health Now and in the Future
2016Co-Authors: S. Karger, M. Scott Bowen, Colleen M. Mcbride, Sheri D. Shully, Muin J. KhouryAbstract:Each paper needs an abstract of up to 200 words. It should contain the following information: Background/Aims/Objective(s), Methods, Results, Conclusion(s). Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page. Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author’s name. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions at www.karger. com/phg/). Color illustrations Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page. Nomenclature, Abbreviations, Symbols and Further Suggestions Human gene symbols: Only official gene symbols of the HUGO Gene Nomenclature Committee (HGNC) are accepted. Authors must obtain or verify the official gene symbol of the gene(s) mapped and indicate that they have done so in the manuscript submitted. This can be accomplished for human genes by contacting Submission Only original papers written in English are considered and should be submitted using the online website at:
-
Genomics in Public Health perspective from the office of Public Health Genomics at the centers for disease control and prevention cdc
Healthcare, 2015Co-Authors: Ridgely Fisk Green, Katherine Kolor, Scott Bowen, W D Dotson, Muin J. KhouryAbstract:The national effort to use genomic knowledge to save lives is gaining momentum, as illustrated by the inclusion of Genomics in key Public Health initiatives, including Healthy People 2020, and the recent launch of the precision medicine initiative. The Office of Public Health Genomics (OPHG) at the Centers for Disease Control and Prevention (CDC) partners with state Public Health departments and others to advance the translation of genome-based discoveries into disease prevention and population Health. To do this, OPHG has adopted an “identify, inform, and integrate” model: identify evidence-based genomic applications ready for implementation, inform stakeholders about these applications, and integrate these applications into Public Health at the local, state, and national level. This paper addresses current and future work at OPHG for integrating Genomics into Public Health programs.
Stefania Boccia - One of the best experts on this subject based on the ideXlab platform.
-
A framework for new practice in Public Health Genomics
European Journal of Public Health, 2015Co-Authors: Hilary Burton, Stefania Boccia, Ron ZimmernAbstract:Sustainable Health systems will require a shift from treatment of established disease to early diagnosis and prevention and the empowerment of citizens to take greater responsibility for their Health. New biomedical and digital science and technologies, alongside the encouragement of societal changes that support individualism can play an important role tailoring interventions to an individual's biology and forming …
-
chief medical officers meeting on implementing a Public Health Genomics approach
Epidemiology biostatistics and public health, 2015Co-Authors: Stefania Boccia, Antonio Federici, Walter Ricciardi, Martin Mckee, Raniero GuerraAbstract:During the Italian Presidency of the Council of European Union, on October, 2014, the Italian Ministry of Health invited the Chief Medical Officers in Rome for a meeting on the European policies of Public Health Genomics. Following reports on the current policies of Public Health Genomics in Italy and Europe, the policy implications for Health systems of advancements in Genomics were discussed. Specifically, participants at the CMOs’ Meeting acknowledged the challenge faced in effectively and responsibly integrating Genomics into Public Health research, policy and practice. Additionally, the participants agreed that the translation process need to be supported by empirical evidence of effectiveness and cost-effectiveness. The participants agreed that the application of genome-based technologies and information for the prevention, diagnosis and treatment of diseases of Public Health significance still holds a great promise. These advances also raise certain ethical, legal and social issues concerning the potential of Genomics to undermine the collectivistic approach in Public Health and thus equity. The CMOs also acknowledge the importance of research on Genomics to improve patienttargeted care and for technological development in EU Member States, and appreciate the role that EU research programs can contribute to this field. • Those present also argued that Public Health professionals and those who are responsible for designing Health systems should engage with the Genomics agenda in order to ensure proper balance, and to make policy makers aware of its relevance; • That the financial burden imposed by genomic-related technologies has the potential to overwhelm the available resources for Health systems and to broaden Health inequalities, highlighting the need for careful planning; • Member States could, in line with their-own national policies on Health, take additional steps to: develop and implement comprehensive strategies or plans in the field, also (1) Section of Hygiene-Institute of Public Health-Faculty of
-
Genomics and Public Health - Genomics and Public Health
A Systematic Review of Key Issues in Public Health, 2015Co-Authors: Stefania Boccia, Ron ZimmernAbstract:This chapter addresses the crucial question of how Genomics knowledge and technologies can currently be integrated into Public Health practice. There has been an astonishing rate of technological advance in genomic science over the last decade since the Public Health Genomics movement was first conceived in the 1990s, though the arrival of Genomics into Health-care practice represents only the beginning of the translational highway. For some, this exponential growth in knowledge promises a future in which Health care is focused much more effectively at the level of the individual. In this chapter, we examine the emerging areas where Public Health and Genomics intersect, the criteria for population screening programmes involving genomic knowledge, and the use of Genomics for evidence-based approaches to forecast and manage disease prevention and prognosis, as well as Health intervention outcomes. We discuss challenges and barriers for implementing evidence-based genomic applications in the Public Health practice. We provide a three-tiered approach to group Public Health Genomics applications based on their readiness for practice. We conclude that coordinated efforts are essential to guide development in genomic medicine, towards an impact on population Health.
-
Public Health Genomics education in post-graduate schools of hygiene and preventive medicine: a cross-sectional survey
BMC medical education, 2014Co-Authors: Carolina Ianuale, Walter Mazzucco, Walter Ricciardi, Carolina Marzuillo, Paolo Villari, Emanuele Leoncini, Stefania BocciaAbstract:Background The relevance of Public Health Genomics (PHG) education among Public Health specialists has been recently acknowledged by the Association of Schools of Public Health in the European Region. The aim of this cross-sectional survey was to assess the prevalence of post-graduate Public Health schools for medical doctors which offer PHG training in Italy.
-
Beyond Public Health Genomics: proposals from an international working group
European journal of public health, 2014Co-Authors: Stefania Boccia, Martin Mc Kee, Róza Ádány, Paolo Boffetta, Hilary Burton, Anne Cambon-thomsen, Martina C. Cornel, J A Muir Gray, Anant Jani, Bartha Maria KnoppersAbstract:Advances in Genomics have crucial implications for Public Health, offering new ways of differentiating individuals and groups within populations that go beyond the measures normally used by Public Health professionals, such as gender, age, socio-economic status, physiological measurements or clinical biomarkers.1 While Public Health has traditionally been concerned with interventions at a population level, genomic medicine seems to promote a vision for Health care that encourages individualism rather than collectivism.2 This tension is apparent in weighing up its consequences. Thus, it may bring benefits in stratifying individuals according to genetic risk, enabling better targeting of preventive and therapeutic interventions. But it may also have harmful consequences undermining the imperative to tackle social and environmental determinants of disease and the collective provision of Health care potentially leading to overdiagnosis/overtreatment; it may fragment the risk pooling that underpins social solidarity; and it may increase the probability of stigmatization and discrimination. Consequently, the Public Health community, with its commitment to equity, must take the opportunity to engage with genomic knowledge, ensuring that it advances the population’s Health. These issues were explored in January 2014 at the inaugural meeting of an international working group on ‘Beyond Public Health Genomics’, convening leading experts in Genomics, Public Health, clinical sciences, systems medicine, law and bioethics, from many disciplines and countries, at the Universita Cattolica del Sacro Cuore in Rome. Its goal, inspired by the 2005 Bellagio statement on Public Health Genomics, defined as the ‘responsible and effective translation of genome-based discovery into population Health,3 was to generate high value-based proposals to foster the evidence base for implementing genomic discoveries in Public Health policy and practice, and to ensure necessary action while accounting for the challenge of needing to fund these workstreams in the current environment of diminishing resources. The contribution of Genomics to …
Andrea H. Brand - One of the best experts on this subject based on the ideXlab platform.
-
Public Health Genomics: the essential part for good governance in Public Health
International journal of public health, 2016Co-Authors: Andrea H. Brand, Nikolaos Evangelatos, Kapaettu SatyamoorthyAbstract:In view of the importance of the report of the German Academy of Sciences (Leopoldina 2015), discussion on the Health impact of Omics was invited (Kunzli 2015). We would like to expand the view previously published in this journal (Razum et al. 2015). Modern accounts of what now constitutes Public Health have broadened the meaning of the latter, which has come to mean any form of collective action that aims to improve the Health of populations (Porter 1998). In that sense, categories, such as medicine, epidemiology and new technologies (to name a few), are species concepts, subjected to a wider genus proximum, Public Health. In this context, the fascinating field of Omics (Genomics, transcriptomics, proteomics, metabolomics, microbiomics, etc.) and Big Data, with its various applications, has already started to revolutionize the landscape of Public Health, since the beginning of the 21st century (Brand et al. 2008). However, individual scholars and academic institutes have failed to catch sight of the current successes of Omics and Big Data, recognize their entire societal potential and envisage the future (Bayer and Galea 2015; Leopoldina 2015). Moreover, misconceptions of the Health impact of Omics have misled scholars and part of the Public to doubt their effectiveness and adopt opinions that hinder the implementation of Omics in Health systems. We, on the other hand, argue that Omics are now an organic part of good governance in Public Health. The idea of modern Public Health without Omics is simply inconceivable! The reasons for this rely on arguments based on both scientific and societal values. Going beyond phenotypes, Omics allow for the detection of Mendelian diseases almost to 100 %. And not only that! Identification of resilient individuals opens new highways towards elucidation of genetic disorders and new treatment approaches (Chen et al. 2016). Newborn screening programs are a reality, a current success of Omics, which allows for timely diagnosis even before clinical presentation and enables improved life- and Healthspan for affected children. Women with BRCA1 mutations, identified through genetic testing and offered intensive preventive options, are also a reality. Yes, it has not been easy for multifactorial or complex diseases, but with the continued thrust, it will be achievable in the foreseeable future. There are already about 1000 genetic tests for multifactorial disorders and hundreds more are currently being tested, with new approaches, such as the diseasome, facilitating the conceptualization of the genome-disease interactions. For the patients with potentially life threatening multifactorial disorders, such as cardiac channelopathies and cardiomyopathies, timely diagnosis and treatment options, are already becoming a reality. Apart from diagnosis, Omics have also been changing the way we approach treatment. An ever growing list of genetic polymorphisms is now used as a basis for predicting response to more than 100 drugs. PharmacoGenomics allow for the identification of patients most likely to respond to a certain treatment, enable tailoring of drug dosage and minimize adverse drug reactions. The importance of pharmacoGenomics becomes even more evident if we take into account that 38–75 % of patients are estimated to be unresponsive to drugs (Lehrach 2015). A third pillar of Omics applications is related to their ability to fully exploit the potential of traditional Public Health interventions. Although a relatively new approach, genetic profiling enables population stratification as to their genetic predisposition and guides prevention programs accordingly, thus rendering them more effective in terms of cost and benefit. In an uncertain global economic landscape, cost effectiveness of any Public Health intervention is of major importance and Omics can help us both optimize the outcome and reduce the costs of our interventions. Effective screening and prevention programs, early diagnosis, proper treatment and minimization of costs enabled by Omics are obvious benefits for both patients and Health care systems. Is that not, after all, the essence of successful Public Health programs? The contribution of Omics to Public Health transcends conventional academic and industrial barriers and transforms Public Health in ways that traditional approaches simply cannot. Apart from Public Health interventions, we also need effective drugs in our armamentarium. In an era when the rate of new drug approvals stagnates, drug development has moved from the classical clinical development approach of the many, sequential, distinct phases, to a more integrative approach with adaptive clinical trial designs. This is a pure effect of the implementation of Omics approaches and has already started delivering its first results (Schulthess et al. 2015). Furthermore, and perhaps even more excitingly, knowledge in the form of integrated and socially meaningful Omic data has increasingly been conceptualized as Public good. Sharing of Omic data from clinical trials enhances Public confidence in clinical trials results and fosters the innovation capability of the biopharmaceutical industry, thus leading to the production of targeted drugs that allow for the realization of personalized medicine. However, the social and economic externalities of Omics do not stop here. Health Data Cooperatives enabled by Omics, such as MIDATA.coop, empower citizens to the benefit of individuals, Healthcare systems and the society (Hafen et al. 2014). From the above, it is obvious that we are in the middle of a major paradigm shift that leads us towards a ‘systems thinking’ as to disease etiology, prevention and treatment (Brand 2011). However, we are confronted with challenges that need to be addressed. It is clear that we will have to go through a period of ‘normal science’ (in the Kuhnian sense) (Kuhn 1962) which will shed light on the constant interactions between the genome and the phenome (Houle et al. 2010). Moreover, the impact of Omics on Public Health cannot be fully realized, unless their implementation and integration in Health care systems are fully deployed. A critical mass has to be reached… Effective implementation of Omics-based technologies requires coordinated actions and appropriate modifications of Public Health and Health governance systems at all levels (Brand et al. 2012). Starting in Germany and followed by other European Member States, significant work towards this direction has been done by the Public Health Genomics European Network (PHGEN) (http://www.phgen.eu) and guidelines have been developed to ensure the maximum impact on Health and economic growth in the Health sector. It is incontrovertible that the traditional approaches based on epidemiology, such as tobacco control, have conferred significant advantages in the Health of populations. However, they seem to have reached their capacity as to the added value they can confer, at least to parts of the population which have already benefited from such interventions (e.g., people who have quitted smoking). On the other hand, Omics have been providing sound evidence of their potential, as an essential part of good governance, to radically transform the landscape in Public Health. Unless the skepticism of traditional Public Health programs towards Omics can present us a sustainable alternative to Omics, there is no other way, beneficial to the population, for them, but to welcome new partners and new approaches to common scopes. The high relevance of the field of Omics for Public Health and Health policy has recently also been expressed by European policymakers. In the Council conclusions on personalized medicine for patients, which has been developed under the Luxembourg Presidency in 2015 (Council 2015), the step-by-step implementation of Public Health Genomics, both at European Union and national level, is encouraged. Public Health Genomics offers a debate platform, where a productive ‘innovation diplomacy’ can find place—we welcome constructive contributions!
-
Bridging Genomics research between developed and developing countries: the Genomic Medicine Alliance
Personalized medicine, 2014Co-Authors: David Neil Cooper, Andrea H. Brand, Vita Dolzan, Paolo Fortina, Federico Innocenti, Ming Ta Michael Lee, Milan Macek, Fahd Al-mulla, Barbara Prainsack, Alessio SquassinaAbstract:The Genomic Medicine Alliance is a global academic research network that aims to establish and strengthen collaborative ties between the various genomic medicine stakeholders. Its focus lies on the translation of scientific research findings into clinical practice. It brings together experts from disciplines including genome informatics, pharmacoGenomics, Public Health Genomics, ethics in Genomics and Health economics, and it is supervised by a 14-member International Scientific Advisory Committee comprising internationally renowned scientists. The Alliance's official journal, Public Health Genomics, offers members a highly respected Publication forum for their original research findings. In the short-to-medium term, the Genomic Medicine Alliance hopes to harmonize research activities between developed and developing countries and to organize educational activities in the field of genomic medicine.
-
Public Health Genomics in Europe
Italian Journal of Public Health, 2012Co-Authors: Stefania Boccia, Andrea H. Brand, Ron Zimmern, Muin J. Khoury, Helmut R. Brand, Peter SchröderAbstract:The challenge of integrating Genomics into Public Health The Human Genome Project was completed in 2003. Expectations are high that new knowledge and technologies arising from the project will soon contribute to the improvement of individual and population Health. Yet, approaches in Public Health have so far not broadly used molecular knowledge of individual genetic susceptibility for achieving their goals. However, in the past decade there has been increasing awareness that advances in Genomics can be utilised in Public Health in the near future. It is our opinion that it is of major importance to start discussion of this option and its possible consequences early enough. This thematic issue starts from the premise that Public Health approaches can and should no longer ignore the advances made in Genomics.We are seeing the emergence of the multidisciplinary field of Public Health Genomics that deals with these opportunities and challenges. According to the statements of an expert group that discussed Public Health Genomics concepts in Bellagio in 2005, Public Health Genomics can be defined as:“The responsible and effective translation of genome-based knowledge and technologies for the benefit of population Health (Bellagio Report).”
-
Analysis of existing international policy evidence in Public Health Genomics: mapping exercise.
Journal of public health research, 2012Co-Authors: Elena V. Syurina, Tobias Schulte In Den Bäumen, Frans J. M. Feron, Andrea H. BrandAbstract:Background . In the last decades we have seen a constant growth in the fields of science related to the use of genome-based Health information. However, there is a gap between basic science research and the Public Health everyday practice. For a successful introduction of genome-based technologies policy actions on the international level are needed. This work represents the initial stage of the PHGEN II (Public Health Genomics European Network II) project. In order to prepare a base for bridging Genomics and Public Health, an inventory study of the existing legislative base dealing with controversies of genome-based knowledge was conducted. The work results in the mapping of the most and the least legislatively covered areas and some preliminary conclusions about the existing gaps. Design and Methods . The collection of the evidence-based policies was done through the PHGEN II project. The mapping covered the meta-level (international, European general guidelines). The expert opinion of the partners of the project was required to reflect on and grade the collected evidence. Results. An analysis of the evidence was made by the area of coverage: using the list of important policy areas for successful introduction of genome-based technologies into Public Health and the Public Health Genomics Wheel (originally Public Health Wheel developed by Institute of Medicine). Conclusions . Severe inequalities in coverage of important issues of Public Health Genomics were found. The most attention was paid to clinical utility and clinical validity of the screening and the protection of human subjects. Important areas such as trade agreements, Public Health Genomics literacy, insurance issues, behaviour modification in response to Genomics results etc. were paid less attention to. For the successful adoption of new technologies on the Public Health level the focus should be not only on the translation to clinical practice, but the translation from bench to Public Health policy and back. Coherent and consistent coverage of all aspects of the translation of genome based information and technologies is of outmost importance.
-
A new Public Health Genomics model for common complex diseases, with an application to common behavioral disorders
Personalized medicine, 2012Co-Authors: Bahar Taneri, Elena Ambrosino, Jim Van Os, Andrea H. BrandAbstract:Aim: In the light of common forms of gene–environment interplay, particularly epiGenomics and ecogenetics, the incorporation of envirome data into Public Health Genomics models becomes necessary. Developing and restructuring Public Health Genomics models is essential within the context of common complex diseases. Materials & methods: We developed a novel theoretical model integrating a gene–environment interaction paradigm into Public Health Genomics, which integrates four main sources of data: personal genome data, personal envirome data, molecular genetic/genomic evidence and environmental factors implicated in gene–environment interactions underlying common complex disease phenotypes. Collectively, this knowledge is fed into Public Health policy development. Results: This model is the first Public Health Genomics model that incorporates gene–environment interactions within the context of common complex disorders, and is applied to behavioral conditions. Conclusion: Our model proposes, for the first tim...
Rodolfo Valdez - One of the best experts on this subject based on the ideXlab platform.
-
a decade of Public Health Genomics in the united states centers for disease control and prevention 1997 2007
Public Health Genomics, 2009Co-Authors: Muin J. Khoury, Marta Gwinn, Katherine Kolor, Scott Bowen, L.a. Bradley, Ralph J. Coates, Nicole F. Dowling, Cynthia A. Moore, J. St. Pierre, Rodolfo ValdezAbstract:Since 1997, the Centers for Disease Control and Prevention (CDC) has collaborated with numerous partners to develop and chart the course of the multidisciplinary field of Public Health Genomics in the
-
Public Health Genomics approach to type 2 diabetes.
Diabetes, 2008Co-Authors: Muin J. Khoury, Rodolfo Valdez, Ann L. AlbrightAbstract:Type 2 diabetes is a leading cause of morbidity and mortality worldwide (1). In the last 15 years, the number of people in the U.S. with diagnosed diabetes has more than doubled. Strong risk factors for type 2 diabetes include age, sex, obesity, physical inactivity, and family history (2). Several measured genetic variants have recently emerged as risk factors for type 2 diabetes. In this commentary, we discuss the impact of new gene discoveries on prediction and prevention of type 2 diabetes. We propose that the new multidisciplinary field of Public Health Genomics can help translate gene discoveries into appropriate actions to reduce the burden of type 2 diabetes in the population. ### Role of genetic factors in type 2 diabetes. It has long been recognized that type 2 diabetes runs in families even though only a few diabetes-related genetic diseases have been identified (3). Until recently, the quest for genetic susceptibility to type 2 diabetes has frustrated researchers. Since the completion of the Human Genome Project in 2003 (4), and the Haplotype Mapping (HapMap) Project in 2005 (5), the stage was set for using large-scale collaborative genome-wide association studies (GWAS) to search for genetic factors for many common diseases of Public Health importance, including type 2 diabetes (6). Since 2007, the scientific community has begun to reap the benefits of GWAS, with >170 studies published and many replicated genetic “hits” found across the genome for a variety of common diseases. These findings fuel expectations that genetic factors can be used to construct susceptibility profiles that will help in the prediction, prevention, and early detection of human diseases, thus ushering in a new era of personalized Health care and disease prevention (7). ### Current findings on the genetics of type 2 diabetes. In this issue, van Hoek et al. (8) and Lango et al. (9) take GWAS findings in type 2 diabetes to the next logical level by …
-
A Decade of Public Health Genomics in the United States: Centers for Disease Control and Prevention 1997–2007
Public health genomics, 2008Co-Authors: Muin J. Khoury, Marta Gwinn, Katherine Kolor, Scott Bowen, L.a. Bradley, Ralph J. Coates, Nicole F. Dowling, Cynthia A. Moore, J. St. Pierre, Rodolfo ValdezAbstract:Since 1997, the Centers for Disease Control and Prevention (CDC) has collaborated with numerous partners to develop and chart the course of the multidisciplinary field of Public Health Genomics in the
Paolo Villari - One of the best experts on this subject based on the ideXlab platform.
-
European survey on knowledge and attitudes of Public Health professionals on Public Health Genomics: Pilot Study
Epidemiology biostatistics and public health, 2017Co-Authors: Annalisa Rosso, E Pitini, Elvira D’andrea, M. Di Marco, Brigid Unim, Carolina Marzuillo, Corrado De Vito, Paolo VillariAbstract:EUROPEAN SURVEY ON KNOWLEDGE AND ATTITUDES OF Public Health PROFESSIONALS ON Public Health Genomics: PILOT STUDY Background: During the past decade a debate has arisen on the possible utility of genomic science for Public Health purposes. Within this context, a survey is being conducted to assess attitudes of European Public Health (PH) professionals belonging to EUPHA network regarding their role in the implementation of Public Health Genomics (PHG), and their knowledge and attitudes regarding genetic testing and the delivery of genetic services. Methods: A pilot on-line survey was conducted on professionals from Sapienza University of Rome and the Vrije University of Amsterdam. The survey tool is composed of 5 sections: Personal details, Professional activity, Knowledge on genetic testing and delivery of genetic services, Attitudes on genetic testing and delivery of genetic services, Attitudes on the role of PH professionals in PHG. Results: 34 people responded to the questionnaire, mostly medical doctors (61,8%). No respondents correctly identified all evidence-based applications of genetic testing. More than one third of respondents agreed that it would be more important to invest resources in the social and environmental causes of ill Health than in genetic testing. Nearly 70% thought that PHG needs to be grounded on evidence of effectiveness, a lower rate agreed ii should be grounded on cost-effectiveness. The rate of agreement with the proposed roles of PH professionals in PHG was very high. Conclusions: This pilot study showed a positive attitude but the need to improve knowledge of PH professionals on PHG. It provided useful input for the implementation of the survey to all members of the EUPHA network.
-
A pilot survey on knowledge and attitudes of Public Health professionals on Public Health Genomics
European Journal of Public Health, 2016Co-Authors: E Pitini, Elvira D’andrea, M. Di Marco, Brigid Unim, Carolina Marzuillo, C De Vito, Paolo VillariAbstract:Background During the past decade a debate has arisen on the possible utility of genomic science for Public Health purposes. Within this context, we aim to conduct a survey to assess the attitudes of European Public Health (PH) professionals belonging to EUPHA network regarding their role in the implementation of Public Health Genomics (PHG), and their knowledge and attitudes regarding genetic testing and the delivery of genetic services. Methods A pilot on-line survey …
-
Public Health Genomics education in post-graduate schools of hygiene and preventive medicine: a cross-sectional survey
BMC medical education, 2014Co-Authors: Carolina Ianuale, Walter Mazzucco, Walter Ricciardi, Carolina Marzuillo, Paolo Villari, Emanuele Leoncini, Stefania BocciaAbstract:Background The relevance of Public Health Genomics (PHG) education among Public Health specialists has been recently acknowledged by the Association of Schools of Public Health in the European Region. The aim of this cross-sectional survey was to assess the prevalence of post-graduate Public Health schools for medical doctors which offer PHG training in Italy.
-
Are Public Health professionals prepared for Public Health Genomics? A cross-sectional survey in Italy
BMC health services research, 2014Co-Authors: Carolina Marzuillo, Elvira D’andrea, Corrado De Vito, Maddalena D'addario, P. Santini, Antonio Boccia, Paolo VillariAbstract:Background Public Health Genomics is an emerging multidisciplinary approach, which aims to integrate genome-based knowledge in a responsible and effective way into Public Health. Despite several surveys performed to evaluate knowledge, attitudes and professional behaviors of physicians towards predictive genetic testing, similar surveys have not been carried out for Public Health practitioners. This study is the first to assess knowledge, attitudes and training needs of Public Health professionals in the field of predictive genetic testing for chronic diseases.